Connected Innovation and Specialty-Specific AI Take Center Stage at Nextech EDGE 2026




Connected Innovation and Specialty-Specific AI Take Center Stage at Nextech EDGE 2026

TAMPA, Fla., March 13, 2026 (GLOBE NEWSWIRE) — Specialty leaders from across the country are gathering at Nextech EDGE 2026, the company’s annual user conference designed to bring together customers, partners, and industry experts to collaborate on the future of specialty care.

Running through March 14 in Orlando, Fla., EDGE creates a shared forum where practices exchange ideas, influence innovation, and explore existing technology built alongside the communities it serves. The event unites providers, administrators, executives, and technology leaders around a common goal of advancing specialty care through connected innovation and specialty-specific artificial intelligence (AI) designed to solve real practice challenges.

“EDGE is an opportunity for us to spend time directly with the practices we serve and better understand the unique demands of each specialty,” said Rusty Frantz, CEO of Nextech. “Those conversations help shape the innovations we’re building, including specialty-specific AI designed to align with real clinical workflows. By listening closely to our customers, we can deliver technology that reduces administrative burden, supports providers in the exam room, and ultimately helps practices deliver better care in a healthcare environment defined by constant change and rising expectations.”
  
Built around customer collaboration, EDGE 2026 highlights how Nextech innovations evolve through ongoing partnership with specialty practices. EDGE will spotlight the next evolution of the Nextech platform, including its new AI assistant alongside advancements in data insights, patient experience, and payments. Attendees will receive exclusive early access to these connected innovations, designed to help practices strengthen performance, protect margins, and elevate patient care through solutions shaped by real-world specialty workflows and feedback.

AI-Powered Clinical Documentation
Cora Scribe is Nextech’s recently launched AI assistant built specifically for ophthalmology. The two-way intelligently integrated scribe listens to natural conversations, understands clinical context, and automatically generates accurate, structured documentation inserted directly into the EHR in near real time.

A Smarter Data Foundation
Nextech is reimagining how data powers the specialty practice by modernizing reporting and standardizing insights across the platform. With a stronger data foundation, practices gain clearer visibility, greater confidence, and the ability to move faster, protect margins, and lead with clarity as innovation continues to unfold.

Patient Experience, Reimagined
EDGE will spotlight major enhancements across the entire patient journey, from smarter acquisition to seamless access and ongoing engagement. These connected innovations, integrated across Nextech solutions and alongside a new intelligent CRM, support personalized communication, referrals, and membership‑driven engagement, extending the patient experience beyond the visit.

Flexible, Frictionless, Embedded Payments
The company also will showcase enhancements to Nextech Payments and expanded offerings designed to deliver a more modern, connected financial experience for both patients and practices. Powered by enhanced payment processing capabilities through Stripe and expanded patient financing with Affirm, these innovations reflect the growing role payments play in the overall patient experience. As healthcare consumers expect greater transparency, flexibility, and convenience, practices benefit from embedded workflows, flexible payment choices, and a simplified end-to-end financial journey that supports access to care while strengthening financial performance.

Beyond product updates, EDGE will deliver two full days of educational sessions tailored to ophthalmology, dermatology, plastic surgery, and med spa practices. Attendees will also gain direct access to Nextech leadership, product experts, and peers, fostering collaborative learning and practical problem-solving.

To learn more about Nextech and its intelligent, connected solutions, visit www.nextech.com.

About Nextech  
Nextech provides intelligent, connected technology that helps specialty practices operate more easily and create meaningful patient experiences. With more than 25 years of expertise in ophthalmology, dermatology, orthopedics, plastic surgery, and med spas, Nextech blends specialty insight with thoughtful innovation to simplify workflows, reduce friction, and support practice growth.

CONTACT: Amanda Wratchford
Nextech Senior Vice President of Marketing
a.wratchford@nextech.com

Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression




Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive Long-Term, and Continue to Produce Insulin

C-Peptide Levels at Month 14 Comparable to Initial Six Months of Study; Results Highlight the Importance of Improved Glycemic Control on Islet Function

Full 14-Month Data to Be Presented Today at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference

Sana is Leveraging Validated HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy, Designed as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose without Insulin or Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application for SC451 in Type 1 Diabetes and Initiate Phase 1 Trial as Early as This Year

SEATTLE, March 13, 2026 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The study is being conducted in partnership with Uppsala University Hospital.

Results from more than 1 year after cell transplantation demonstrate sustained survival and function of pancreatic beta cells, as measured by the presence of circulating C-peptide, a biomarker of endogenous insulin production by the transplanted beta cells. C-peptide levels also increase in response to a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. Fasting and MMTT-stimulated C-peptide levels at month 14 are comparable to those observed in the first six months of the study and exceed levels measured at months 9 and 12. Between months 12 and 14, the patient achieved tighter glycemic control, and the improved insulin secretion at month 14 underscores the importance of glucose control in optimizing pancreatic beta cell function. No safety issues were identified in the study.

“We are pleased to share the results through 14 months from this first-in-human study transplanting hypoimmune-modified primary islet cells into a patient with type 1 diabetes,” said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “These findings build upon previously presented data and continue to show no safety issues, along with continued immune evasion, survival, and function of the transplanted cells. Importantly, the results demonstrate the positive impact of improved glucose control on beta cell function and the dynamic functional capacity of beta cells transplanted in a single low dose without immunosuppression. This work suggests that the hypoimmune technology has the potential to enable a functional cure for type 1 diabetes without immunosuppression, and we look forward to working with Sana as it brings forward SC451, a more scalable approach, at higher doses.”

“These data continue to highlight the potential for HIP-modified cells to survive, function, and evade immune detection long-term in people post-transplant, a finding that we believe could have broad impact in type 1 diabetes and beyond,” said Steve Harr, MD, Sana’s President and CEO. “The data presented today also demonstrate how improvement in glycemic control – which is anticipated with higher doses of hypoimmune islets – can further enhance the function of these cells. We remain focused on advancing SC451, a HIP-modified stem cell-derived islet cell therapy, into the clinic and expect to file an investigational new drug application (IND) and initiate a Phase 1 trial as early as this year. Our goal is to offer patients a single treatment that delivers durable, normal blood glucose without the need for exogenous insulin or immunosuppression, and we look forward to continuing our collaboration with Dr. Carlsson and his colleagues at Uppsala University to advance this vision.”

Primary islet cell transplantation with immunosuppression is an established procedure in type 1 diabetes in which allogeneic pancreatic islet cells are isolated from a deceased donor’s pancreas and transplanted into a patient with a goal of normal blood glucose and insulin independence. As with whole-organ transplants, suppression of the patient’s immune system has historically been required to prevent immune rejection of allogeneic transplanted cells and resurgence of the inciting autoimmune attack. Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells and, in type 1 diabetes, to also evade autoimmune rejection of pancreatic beta cells. UP421 was derived from the islet cells of a deceased donor and transplanted with no immunosuppression, and the survival of the UP421 cells provides evidence that they evade both allogeneic and autoimmune detection.

About the Uppsala University Hospital Investigator-Sponsored Study of UP421 in Type 1 Diabetes
The investigator-sponsored study of UP421 is supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust. The study evaluates whether HIP-modified insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of simultaneous treatment with immunosuppressive medicines. To do this, UP421 is engineered using Sana’s HIP platform at Oslo University Hospital. The study involves intramuscular surgical transplantation of HIP-modified primary islet cells into the forearm of patients with type 1 diabetes. The primary objective of the study is to investigate the safety of UP421 transplantation in patients with type 1 diabetes, with secondary endpoints including cell survival, immune evasion, and C-peptide production. Circulating C-peptide is a measure of endogenous insulin production. This first-in-human study examines a low dose of HIP-modified primary islets to initially establish the safety and function of HIP-modified islets without immunosuppression and, as a result, is not intended to show improvement in glycemia and/or reduction in exogenous insulin administration.

Results of the study at 14 months after islet cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase during an MMTT, consistent with insulin secretion in response to a meal. At baseline, the patient had undetectable C-peptide both fasting and during an MMTT. 52-week PET-MRI scanning also demonstrated islet cells at the transplant site, a forearm muscle. The HIP platform has not only achieved proof-of-concept in humans but has also shown continuation of effect with long-term evasion of immune recognition, supporting its potential broad application for allogeneic transplantation without immunosuppression.

About the Sana Biotechnology Hypoimmune (HIP) Platform
Sana’s HIP platform is designed to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression. We are applying our HIP technology to develop therapeutic candidates at scale, including pluripotent stem cells, which can then be differentiated into multiple cell types, including pancreatic islet cells. We and our collaborators have generated significant foundational intellectual property in the area. Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells can evade both the adaptive and innate arms of the immune system while retaining their activity. Sana’s most advanced program using this platform is its stem cell-derived pancreatic islet cell program for type 1 diabetes.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates, and technology platforms, including its preclinical, clinical, and regulatory development plans and timing expectations, including the potential timing of INDs and clinical trials for its SC451 program and the dose levels to be evaluated; the potential ability of SC451 to be administered as a one-time treatment for patients with type 1 diabetes, to provide a more scalable approach, and to achieve durable, normal blood glucose without exogenous insulin or immunosuppression; the potential impact and significance of data from the UP421 study of islet cell transplantation without immunosuppression in a patient with type 1 diabetes (“Study”), including the potential to transplant insulin-secreting cells and develop a functional cure for the treatment of type 1 diabetes without immunosuppression; expectations regarding the presentation at the Advanced Technologies & Treatments for Diabetes conference; the ability of the HIP platform to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression and, in type 1 diabetes, enable pancreatic beta cells to overcome autoimmune rejection, to have broad application for allogeneic transplantation without immunosuppression, including in diabetes, and to be applied to develop therapeutic candidates at scale, including pluripotent stem cells that can be differentiated into multiple cell types; the potential safety and long-term survival, function, and evasion of immune detection of HIP-modified cells with no immunosuppression, including the potential impact of glycemic control on islet and beta cell function and the dynamic functional capacity of beta cells transplanted in a single low dose without immunosuppression; expectations with respect to the impact of the dose level of hypoimmune islets on glycemic control; the potential application of the learnings from the Study to the Company’s SC451 program; and statements made by Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, and by the Company’s President and CEO. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission (SEC) reports, including but not limited to its Annual Report on Form 10-K dated March 3, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com

Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression




Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive Long-Term, and Continue to Produce Insulin

C-Peptide Levels at Month 14 Comparable to Initial Six Months of Study; Results Highlight the Importance of Improved Glycemic Control on Islet Function

Full 14-Month Data to Be Presented Today at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference

Sana is Leveraging Validated HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy, Designed as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose without Insulin or Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application for SC451 in Type 1 Diabetes and Initiate Phase 1 Trial as Early as This Year

SEATTLE, March 13, 2026 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The study is being conducted in partnership with Uppsala University Hospital.

Results from more than 1 year after cell transplantation demonstrate sustained survival and function of pancreatic beta cells, as measured by the presence of circulating C-peptide, a biomarker of endogenous insulin production by the transplanted beta cells. C-peptide levels also increase in response to a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. Fasting and MMTT-stimulated C-peptide levels at month 14 are comparable to those observed in the first six months of the study and exceed levels measured at months 9 and 12. Between months 12 and 14, the patient achieved tighter glycemic control, and the improved insulin secretion at month 14 underscores the importance of glucose control in optimizing pancreatic beta cell function. No safety issues were identified in the study.

“We are pleased to share the results through 14 months from this first-in-human study transplanting hypoimmune-modified primary islet cells into a patient with type 1 diabetes,” said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “These findings build upon previously presented data and continue to show no safety issues, along with continued immune evasion, survival, and function of the transplanted cells. Importantly, the results demonstrate the positive impact of improved glucose control on beta cell function and the dynamic functional capacity of beta cells transplanted in a single low dose without immunosuppression. This work suggests that the hypoimmune technology has the potential to enable a functional cure for type 1 diabetes without immunosuppression, and we look forward to working with Sana as it brings forward SC451, a more scalable approach, at higher doses.”

“These data continue to highlight the potential for HIP-modified cells to survive, function, and evade immune detection long-term in people post-transplant, a finding that we believe could have broad impact in type 1 diabetes and beyond,” said Steve Harr, MD, Sana’s President and CEO. “The data presented today also demonstrate how improvement in glycemic control – which is anticipated with higher doses of hypoimmune islets – can further enhance the function of these cells. We remain focused on advancing SC451, a HIP-modified stem cell-derived islet cell therapy, into the clinic and expect to file an investigational new drug application (IND) and initiate a Phase 1 trial as early as this year. Our goal is to offer patients a single treatment that delivers durable, normal blood glucose without the need for exogenous insulin or immunosuppression, and we look forward to continuing our collaboration with Dr. Carlsson and his colleagues at Uppsala University to advance this vision.”

Primary islet cell transplantation with immunosuppression is an established procedure in type 1 diabetes in which allogeneic pancreatic islet cells are isolated from a deceased donor’s pancreas and transplanted into a patient with a goal of normal blood glucose and insulin independence. As with whole-organ transplants, suppression of the patient’s immune system has historically been required to prevent immune rejection of allogeneic transplanted cells and resurgence of the inciting autoimmune attack. Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells and, in type 1 diabetes, to also evade autoimmune rejection of pancreatic beta cells. UP421 was derived from the islet cells of a deceased donor and transplanted with no immunosuppression, and the survival of the UP421 cells provides evidence that they evade both allogeneic and autoimmune detection.

About the Uppsala University Hospital Investigator-Sponsored Study of UP421 in Type 1 Diabetes
The investigator-sponsored study of UP421 is supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust. The study evaluates whether HIP-modified insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of simultaneous treatment with immunosuppressive medicines. To do this, UP421 is engineered using Sana’s HIP platform at Oslo University Hospital. The study involves intramuscular surgical transplantation of HIP-modified primary islet cells into the forearm of patients with type 1 diabetes. The primary objective of the study is to investigate the safety of UP421 transplantation in patients with type 1 diabetes, with secondary endpoints including cell survival, immune evasion, and C-peptide production. Circulating C-peptide is a measure of endogenous insulin production. This first-in-human study examines a low dose of HIP-modified primary islets to initially establish the safety and function of HIP-modified islets without immunosuppression and, as a result, is not intended to show improvement in glycemia and/or reduction in exogenous insulin administration.

Results of the study at 14 months after islet cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase during an MMTT, consistent with insulin secretion in response to a meal. At baseline, the patient had undetectable C-peptide both fasting and during an MMTT. 52-week PET-MRI scanning also demonstrated islet cells at the transplant site, a forearm muscle. The HIP platform has not only achieved proof-of-concept in humans but has also shown continuation of effect with long-term evasion of immune recognition, supporting its potential broad application for allogeneic transplantation without immunosuppression.

About the Sana Biotechnology Hypoimmune (HIP) Platform
Sana’s HIP platform is designed to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression. We are applying our HIP technology to develop therapeutic candidates at scale, including pluripotent stem cells, which can then be differentiated into multiple cell types, including pancreatic islet cells. We and our collaborators have generated significant foundational intellectual property in the area. Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells can evade both the adaptive and innate arms of the immune system while retaining their activity. Sana’s most advanced program using this platform is its stem cell-derived pancreatic islet cell program for type 1 diabetes.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates, and technology platforms, including its preclinical, clinical, and regulatory development plans and timing expectations, including the potential timing of INDs and clinical trials for its SC451 program and the dose levels to be evaluated; the potential ability of SC451 to be administered as a one-time treatment for patients with type 1 diabetes, to provide a more scalable approach, and to achieve durable, normal blood glucose without exogenous insulin or immunosuppression; the potential impact and significance of data from the UP421 study of islet cell transplantation without immunosuppression in a patient with type 1 diabetes (“Study”), including the potential to transplant insulin-secreting cells and develop a functional cure for the treatment of type 1 diabetes without immunosuppression; expectations regarding the presentation at the Advanced Technologies & Treatments for Diabetes conference; the ability of the HIP platform to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression and, in type 1 diabetes, enable pancreatic beta cells to overcome autoimmune rejection, to have broad application for allogeneic transplantation without immunosuppression, including in diabetes, and to be applied to develop therapeutic candidates at scale, including pluripotent stem cells that can be differentiated into multiple cell types; the potential safety and long-term survival, function, and evasion of immune detection of HIP-modified cells with no immunosuppression, including the potential impact of glycemic control on islet and beta cell function and the dynamic functional capacity of beta cells transplanted in a single low dose without immunosuppression; expectations with respect to the impact of the dose level of hypoimmune islets on glycemic control; the potential application of the learnings from the Study to the Company’s SC451 program; and statements made by Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, and by the Company’s President and CEO. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission (SEC) reports, including but not limited to its Annual Report on Form 10-K dated March 3, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com

Blue Cross and Blue Shield of Minnesota Advances Collaborative Efforts to Improve Outcomes and Close Gaps in Care




Blue Cross and Blue Shield of Minnesota Advances Collaborative Efforts to Improve Outcomes and Close Gaps in Care

Excellence in Quality and Outcomes (EQO) Program establishes a shared-data, partnership-driven approach to improving health outcomes

EAGAN, Minn., March 13, 2026 (GLOBE NEWSWIRE) — Blue Cross and Blue Shield of Minnesota announced continued progress in its Excellence in Quality and Outcomes (EQO) Certification Program, a key initiative designed to strengthen healthcare quality and close gaps in care through deeper collaboration with provider systems. While Blue Cross administers multiple quality-focused initiatives, EQO serves as a complementary approach that brings providers and Blue Cross together through shared data, aligned goals and a collective learning process to improve outcomes for key populations and the communities they serve.

“The EQO program allows for Blue Cross to partner with care systems through a structured, multi-year certification framework,” said Dr. Mark Steffen, Chief Medical Officer at Blue Cross and Blue Shield of Minnesota. “This shared approach offers tools, resources, and accountability that support providers as they strengthen care for communities that face barriers to health.”

The inaugural EQO cohort consists of provider care systems that chose to participate in this rigorous improvement process, demonstrating a strong commitment to organizational learning and continuous advancement.

“We appreciate and value every care system that participated in the inaugural cohort,” Steffen added. “At every level of participation, we acknowledge the dedication these organizations bring to improving care for Minnesotans.”

Fairview emphasized the benefit of engaging in a structured program that strengthens improvement efforts, with Taj Mustapha, MD, Chief Strategy Officer at Fairview, noting, “We joined the EQO program because it reinforces the importance of delivering care that’s centered on the real needs of the people and communities we serve. The structure helps us understand where we’re doing well and where we can do better so we can continue strengthening care and outcomes for every patient who relies on us.”

As part of its expansion plans, Blue Cross is recruiting additional provider care systems to join the 2026 cycle, which opened 3/1/2026. Providers interested in structured improvement tools, meaningful support, and statewide recognition can learn more by contacting EQO-Certification@bluecrossmn.com or visiting Blue Cross and Blue Shield of MN EQO Certification Program.

About Blue Cross and Blue Shield of Minnesota
For more than 90 years, Blue Cross and Blue Shield of Minnesota (Bluecrossmn.com) has supported our members by ensuring access to high quality care at an affordable price. Our 3 million members can be found in every Minnesota county, all 50 states and on four continents. Blue Cross and Blue Shield of Minnesota is an independent licensee of the Blue Cross and Blue Shield Association.

Blue Cross and Blue Shield of Minnesota Advances Collaborative Efforts to Improve Outcomes and Close Gaps in Care




Blue Cross and Blue Shield of Minnesota Advances Collaborative Efforts to Improve Outcomes and Close Gaps in Care

Excellence in Quality and Outcomes (EQO) Program establishes a shared-data, partnership-driven approach to improving health outcomes

EAGAN, Minn., March 13, 2026 (GLOBE NEWSWIRE) — Blue Cross and Blue Shield of Minnesota announced continued progress in its Excellence in Quality and Outcomes (EQO) Certification Program, a key initiative designed to strengthen healthcare quality and close gaps in care through deeper collaboration with provider systems. While Blue Cross administers multiple quality-focused initiatives, EQO serves as a complementary approach that brings providers and Blue Cross together through shared data, aligned goals and a collective learning process to improve outcomes for key populations and the communities they serve.

“The EQO program allows for Blue Cross to partner with care systems through a structured, multi-year certification framework,” said Dr. Mark Steffen, Chief Medical Officer at Blue Cross and Blue Shield of Minnesota. “This shared approach offers tools, resources, and accountability that support providers as they strengthen care for communities that face barriers to health.”

The inaugural EQO cohort consists of provider care systems that chose to participate in this rigorous improvement process, demonstrating a strong commitment to organizational learning and continuous advancement.

“We appreciate and value every care system that participated in the inaugural cohort,” Steffen added. “At every level of participation, we acknowledge the dedication these organizations bring to improving care for Minnesotans.”

Fairview emphasized the benefit of engaging in a structured program that strengthens improvement efforts, with Taj Mustapha, MD, Chief Strategy Officer at Fairview, noting, “We joined the EQO program because it reinforces the importance of delivering care that’s centered on the real needs of the people and communities we serve. The structure helps us understand where we’re doing well and where we can do better so we can continue strengthening care and outcomes for every patient who relies on us.”

As part of its expansion plans, Blue Cross is recruiting additional provider care systems to join the 2026 cycle, which opened 3/1/2026. Providers interested in structured improvement tools, meaningful support, and statewide recognition can learn more by contacting EQO-Certification@bluecrossmn.com or visiting Blue Cross and Blue Shield of MN EQO Certification Program.

About Blue Cross and Blue Shield of Minnesota
For more than 90 years, Blue Cross and Blue Shield of Minnesota (Bluecrossmn.com) has supported our members by ensuring access to high quality care at an affordable price. Our 3 million members can be found in every Minnesota county, all 50 states and on four continents. Blue Cross and Blue Shield of Minnesota is an independent licensee of the Blue Cross and Blue Shield Association.

Sienna Announces March Dividend




Sienna Announces March Dividend

MARKHAM, Ontario, March 13, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of March 2026, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on April 15, 2026 to shareholders of record as at March 31, 2026.  

The Company’s dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

Sienna has a Dividend Reinvestment Plan (the “DRIP”) which allows eligible shareholders of the Company to direct that their cash dividends be reinvested in additional Common Shares. Common Shares issued pursuant to the DRIP are issued from treasury at a 3% discount from the market price. Participation in the DRIP is optional and shareholders who do not wish to participate in the DRIP will continue to receive cash dividends. A complete copy of the DRIP is available under the Investors section of the Company’s website.

About Sienna Senior Living

Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,000 employees are passionate about cultivating happiness in daily life. For more information, please visit  www.siennaliving.ca.

For further information, please contact:
David Hung
Chief Financial Officer & Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca

Sienna Announces March Dividend




Sienna Announces March Dividend

MARKHAM, Ontario, March 13, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of March 2026, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on April 15, 2026 to shareholders of record as at March 31, 2026.  

The Company’s dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

Sienna has a Dividend Reinvestment Plan (the “DRIP”) which allows eligible shareholders of the Company to direct that their cash dividends be reinvested in additional Common Shares. Common Shares issued pursuant to the DRIP are issued from treasury at a 3% discount from the market price. Participation in the DRIP is optional and shareholders who do not wish to participate in the DRIP will continue to receive cash dividends. A complete copy of the DRIP is available under the Investors section of the Company’s website.

About Sienna Senior Living

Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,000 employees are passionate about cultivating happiness in daily life. For more information, please visit  www.siennaliving.ca.

For further information, please contact:
David Hung
Chief Financial Officer & Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca